# Gerd Horneff

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 79 papers | 4,625 citations | 109264 35 h-index | 102432 66 g-index |
| 93 all docs | 93 docs citations | 93 times ranked | 3134 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis. New England Journal of Medicine, 2012, 367, 2396-2406. | 13.9 | 588 |
| 2 | Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2008, 359, 810-820. | 13.9 | 530 |
| 3 | Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Annals of the Rheumatic Diseases, 2015, 74, 1110-1117. | 0.5 | 251 |
| 4 | Leflunomide or Methotrexate for Juvenile Rheumatoid Arthritis. New England Journal of Medicine, 2005, 352, 1655-1666. | 13.9 | 216 |
| 5 | Longâ€term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis and Rheumatism, 2010, 62, 1792-1802. | 6.7 | 204 |
| 6 | Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2018, 77, annrheumdis-2018-213030. | 0.5 | 183 |
| 7 | Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis. Clinical Immunology, 2012, 142, 176-193. | 1.4 | 106 |
| 8 | Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Annals of the Rheumatic Diseases, 2014, 73, 1114-1122. | 0.5 | 106 |
| 9 | Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial. Annals of the Rheumatic Diseases, 2018, 77, 21-29. | 0.5 | 96 |
| 10 | Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Annals of the Rheumatic Diseases, 2016, 75, 855-861. | 0.5 | 86 |
| 11 | A Randomized, Doubleâ€Blind, Placeboâ€Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitisâ€Related Arthritis. Arthritis Care and Research, 2015, 67, 1503-1512. | 1.5 | 84 |
| 12 | Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719. | 0.5 | 79 |
| 13 | Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. Arthritis Research and Therapy, 2017, 19, 256. | 1.6 | 75 |
| 14 | Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatric Rheumatology, 2018, 16, 7. | 0.9 | 72 |
| 15 | Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Research and Therapy, 2018, 20, 285. | 1.6 | 71 |
| 16 | Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry. Arthritis and Rheumatology, 2014, 66, 2580-2589. | 2.9 | 69 |
| 17 | Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology, 2011, 50, 214-221. | 0.9 | 68 |
| 18 | Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Research and Therapy, 2016, 18, 272. | 1.6 | 68 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept. Journal of Rheumatology, 2011, 38, 1441-1446. | 1.0 | 66 |
| 20 | Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Research and Therapy, 2012, 14, R230. | 1.6 | 65 |
| 21 | Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatric Rheumatology, 2017, 15, 86. | 0.9 | 64 |
| 22 | The majority of newly diagnosed patients with juvenile idiopathic arthritis reach an inactive disease state within the first year of specialised care: data from a German inception cohort. RMD Open, 2015, 1, e000074. | 1.8 | 63 |
| 23 | Risk of Serious Infection in Juvenile Idiopathic Arthritis Patients Associated With Tumor Necrosis Factor Inhibitors and Disease Activity in the German Biologics in Pediatric Rheumatology Registry. Arthritis Care and Research, 2017, 69, 552-560. | 1.5 | 62 |
| 24 | MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis. Arthritis Research and Therapy, 2015, 17, 200. | 1.6 | 60 |
| 25 | Efficacy and Safety of Etanercept in Patients With the Enthesitisâ€Related Arthritis Category of Juvenile Idiopathic Arthritis: Results From a Phase III Randomized, Doubleâ€Blind Study. Arthritis and Rheumatology, 2015, 67, 2240-2249. | 2.9 | 59 |
| 26 | Time of Diseaseâ€Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drugâ€Free Remission in Young Adulthood. Arthritis Care and Research, 2019, 71, 471-481. | 1.5 | 55 |
| 27 | Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opinion on Biological Therapy, 2013, 13, 361-376. | 1.4 | 54 |
| 28 | Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. Rheumatology, 2009, 48, 916-919. | 0.9 | 52 |
| 29 | Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology, 2011, 50, 230-236. | 0.9 | 52 |
| 30 | Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry. Arthritis Care and Research, 2015, 67, 1529-1535. | 1.5 | 52 |
| 31 | Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics. Journal of Rheumatology, 2015, 42, 2160-2165. | 1.0 | 47 |
| 32 | Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. Journal of Rheumatology, 2016, 43, 816-824. | 1.0 | 46 |
| 33 | Subcutaneous Abatacept in Patients With Polyarticularâ€Course Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2018, 70, 1144-1154. | 2.9 | 45 |
| 34 | Biologic-Associated Infections in Pediatric Rheumatology. Current Rheumatology Reports, 2015, 17, 66. | 2.1 | 42 |
| 35 | Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatric Rheumatology, 2020, 18, 17. | 0.9 | 41 |
| 36 | Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease. Journal of Pediatrics, 2018, 201, 166-175.e3. | 0.9 | 37 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 969-974. | 0.5 | 36 |
| 38 | Safety of biologic therapies for the treatment of juvenile idiopathic arthritis. Expert Opinion on Drug Safety, 2015, 14, 1111-1126. | 1.0 | 35 |
| 39 | Protocols on classification, monitoring and therapy in childrenâ€™s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis. Pediatric Rheumatology, 2017, 15, 78. | 0.9 | 35 |
| 40 | Baricitinib in therapy of COPA syndrome in a 15-year-old girl. European Journal of Rheumatology, 2020, 7, 78-81. | 1.3 | 32 |
| 41 | Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Research and Therapy, 2019, 21, 125. | 1.6 | 31 |
| 42 | Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology, 2014, 53, 1245-1249. | 0.9 | 28 |
| 43 | Treatment strategies for juvenile idiopathic arthritis. Expert Opinion on Pharmacotherapy, 2009, 10, 3049-3060. | 0.9 | 27 |
| 44 | Definition of improvement in juvenile idiopathic arthritis using the Juvenile Arthritis Disease Activity Score. Rheumatology, 2014, 53, 1229-1234. | 0.9 | 27 |
| 45 | Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry. Arthritis Research and Therapy, 2020, 22, 258. | 1.6 | 27 |
| 46 | Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA. Annals of the Rheumatic Diseases, 2018, 77, 996-1002. | 0.5 | 26 |
| 47 | Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71. | 1.6 | 25 |
| 48 | A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS. Journal of Experimental Medicine, 2021, 218, . | 4.2 | 25 |
| 49 | Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatology International, 2007, 27, 383-386. | 1.5 | 24 |
| 50 | S2k guidelines for the treatment of psoriasis in children and adolescents â€“ Short version part 2. JDDG - Journal of the German Society of Dermatology, 2019, 17, 959-973. | 0.4 | 24 |
| 51 | Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatology International, 2007, 28, 153-156. | 1.5 | 22 |
| 52 | S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 547-554. | 1.0 | 22 |
| 53 | Long-term surveillance of biologic therapies in systemic-onset juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology, 2020, 59, 2287-2298. | 0.9 | 21 |
| 54 | Predictors of response to methotrexate in juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, 35. | 0.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Longâ€Term Safety Data from the German <scp>BIKER</scp> Registry. ACR Open Rheumatology, 2020, 2, 37-47. | 0.9 | 19 |
| 56 | Infliximab in two patients with juvenile ankylosing spondylitis. Rheumatology International, 2004, 24, 173-176. | 1.5 | 18 |
| 57 | Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?. Nature Reviews Rheumatology, 2014, 10, 682-690. | 3.5 | 17 |
| 58 | Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Sevenâ€Year Interim Results. Arthritis Care and Research, 2020, 72, 1420-1430. | 1.5 | 17 |
| 59 | Update on malignancies in children with juvenile idiopathic arthritis in the German BIKER Registry. Clinical and Experimental Rheumatology, 2016, 34, 1113-1120. | 0.4 | 17 |
| 60 | Macrophage activation syndrome as the initial manifestation of tumour necrosis factor receptor 1-associated periodic syndrome (TRAPS). Clinical and Experimental Rheumatology, 2013, 31, 99-102. | 0.4 | 15 |
| 61 | Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry. Rheumatology International, 2021, 41, 751-762. | 1.5 | 13 |
| 62 | Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritisâ€"results from a JIA biologic registry. Rheumatology, 2019, 59, 603-612. | 0.9 | 11 |
| 63 | The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis. Expert Opinion on Pharmacotherapy, 2016, 17, 703-714. | 0.9 | 10 |
| 64 | Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial. Pediatric Rheumatology, 2021, 19, 5. | 0.9 | 9 |
| 65 | Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. Rheumatology, 2022, 61, 2524-2534. | 0.9 | 9 |
| 66 | Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis. Arthritis Research and Therapy, 2021, 23, 118. | 1.6 | 8 |
| 67 | The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clinical and Experimental Rheumatology, 2018, 36, 920-928. | 0.4 | 8 |
| 68 | Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis â€“ data from the German AID-registry. Pediatric Rheumatology, 2021, 19, 38. | 0.9 | 7 |
| 69 | Functional flow cytometry of monocytes for routine diagnosis of innate primary immunodeficiencies. Journal of Allergy and Clinical Immunology, 2020, 145, 434-437.e4. | 1.5 | 5 |
| 70 | Efficacy and Safety of Etanercept Biosimilars Compared With the Originator for Treatment of Juvenile Arthritis: A Prospective Observational Study. ACR Open Rheumatology, 2021, 3, 779-787. | 0.9 | 4 |
| 71 | Spontaneous regression of Epstein-Barr virusassociated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept. European Journal of Rheumatology, 2017, 4, 136-138. | 1.3 | 3 |
| 72 | Progress in pediatric rheumatology: apprehend the opportunities of the future without forgetting the lessons from the past. Rheumatology International, 2011, 31, 1259-62. | 1.5 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | The German version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 211-218. | 1.5 | 2 |
| 74 | Reply to the article: Initiating etanercept in a once weekly dose in children with juvenile idiopathic arthritis by Femke H.M. Prince, Lisette W.A. van Suijlekom-Smit. Rheumatology International, 2008, 28, 399-399. | 1.5 | 1 |
| 75 | Treatment options with biologics for juvenile idiopathic arthritis. International Journal of Clinical Rheumatology, 2011, 6, 305-323. | 0.3 | 1 |
| 76 | Update â€“ Systemische juvenile Arthritis. Kinder- Und Jugendmedizin, 2021, 21, 349-357. | 0.0 | 1 |
| 77 | Tumour necrosis factor inhibitors in enthesitis related arthritis and juvenile spondylarthropathies. Expert Opinion on Orphan Drugs, 2018, 6, 127-140. | 0.5 | 0 |
| 78 | PolyartikulÃre Verlaufsformen der juvenilen idiopathischen Arthritis. Springer Reference Medizin, 2021, , 1-27. | 0.0 | 0 |
| 79 | Zytokin-Inhibitoren in der pÃdiatrischen Rheumatologie. Springer Reference Medizin, 2021, , 1-12. | 0.0 | 0 |